# Influences of Angiotensin-neprilysin Inhibition on Sympathetic Activity in Heart Failure

> **NCT03415906** · PHASE2 · WITHDRAWN · sponsor: **Hannover Medical School**

## Conditions studied

- Heart Failure

## Interventions

- **COMBINATION_PRODUCT:** sacubitril+valsartan
- **DRUG:** valsartan

## Key facts

- **NCT ID:** NCT03415906
- **Lead sponsor:** Hannover Medical School
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2017-12-14
- **Primary completion:** 2018-09-06
- **Final completion:** 2018-09-06
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Difficulties in recruiting patients
- **Last updated:** 2018-10-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03415906

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03415906, "Influences of Angiotensin-neprilysin Inhibition on Sympathetic Activity in Heart Failure". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03415906. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*